Authors
Latest:
Build Brand Trust with Communities of Color Beyond COVIDWhen it comes to vaccine hesitancy or reluctance, there have always been concerns around the public's belief and attitude. This is especially apparent among blacks and other minority groups, whose concerns can stem from historic injustices that fueled mistrust. The COVID era has presented an opportunity to convert many who are ready to engage via transparency and by initiating trust through marketing.
Latest:
The Transformative Potential of AI in the Pharmaceutical Industry: Opportunities and CautionsThe technology provides the industry with many opportunities, but it must also navigate a complex regulatory landscape.
Latest:
Can AI Point the Way?Coverage highlights from the September issue of Pharmaceutical Executive offer another example of the accelerated convergence—and future hope—of AI and healthcare.
Latest:
China 2021: The NRDL ReadoutChina‘s 2021 National Reimbursement Drug List (NRDL) results are finally out, and this year features another major expansion of the NRDL formulary, with ongoing emphasis on innovations and some much anticipated breakthroughs in rare disease drug inclusions.
Latest:
Rethinking Audience Modeling: AI, Regulations, & MoreThe intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.
Latest:
New Bespoke Gene Therapy Consortium Is Welcome DevelopmentFor biopharma innovation to succeed and accelerate, companies must stop duplicating their efforts and share valuable information.
Latest:
Why Pharma Should Develop a Core Digital OfferingHow can pharma create solutions that are effective, can provide long-term value, and will actually be adopted by HCPs and patients?
Latest:
Rx Power Struggle: How Pharma can Flip the PBM ScriptThe industry holds the key to true change to the drug access landscape.
Latest:
Orphan Drugs: From Niche to MainstreamLarger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
Latest:
Elevate and De-Risk Your Drug Portfolio Strategy With AIWebinar Date/Time: Wed, Aug 28, 2024 11:00 AM EDT
Latest:
Making the Grade: Registries as Sources of Regulatory-Grade RWEDr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of the PPD clinical research business of Thermo Fisher Scientific, covers key considerations for choosing registries.
Latest:
How AI is Shaping KOL and DOL IdentificationAs drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.
Latest:
[Sponsored Content] Patient Engagement Throughout the Entire Product LifecycleIn the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.
Latest:
Personalizing Pharma: Overcoming Challenges to Drive Digital Customer EngagementAs HCPs continue to face time constraints and information overload, delivering relevant and personalized content becomes increasingly critical.
Latest:
HEOR: From Proving Product Value to Proving Its Own WorthThe recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Latest:
A Risk-Reward Reset: Getting Serious About Social MediaAs the digital medium poses new threats to brand equity and public safety for pharma, what can drugmakers do to better balance its essential communications benefits with the risks?
Latest:
The Real Cost of State Drug Importation Programs? Patient SafetyImporting drugs from Canada may increase the risk of US citizens being exposed to unsafe medicines.
Latest:
Maximizing China Access for Innovative TherapiesTo maximize the potential of innovative therapies in the Chinese market, it’s important to have a holistic view of the full range of options and levers, prioritize and sequence the ones with the highest impacts, and develop an integrated strategy tailored to address the country’s unmet needs.
Latest:
How to Make Your Meetings with HCPs More Insightful and SuccessfulEncounters with healthcare providers (HCPs) requires diligent preparation. Beyond understanding the value of the therapies you're offering, all touchpoints and conversations are of the highest importance - through sharing research, new ideas, and how you can support HCPs, you gain valuable, relevant insights that inform your relationship with HCPs and help them blossom.
Latest:
Evolution of Prostate Cancer Treatment Gathers SpeedAmy Butcher evaluates the current treatment options for prostate cancer and the looks to the future as clinical outcomes evolve.
Latest:
Creating Data-driven, Personalized User ExperiencesIn this video Akeel Williams, VP of Strategy and Operations, Manufacturer Solutions, explains how GoodRx uses data to continuously improve its platform for patients and providers.
Latest:
Agile, Microlearning and Engaging Training for Clinical Trial Sites: A Strategic Approach to knowledge and learning management for Biotech SponsorsBridging the gap in data utilization and knowledge/learning management is crucial for successful drug development.
Latest:
Successful Digital Transformation Depends on Quality Customer DataCompanies recognize that their success with digital starts with accurate customer data, but many struggle to manage the overwhelming volume of different data types from hundreds of sources.
Latest:
Five Steps for Automating the Pharmacovigilance ProcessHere’s how pharma businesses can speed the handling of adverse events, reduce costs, improve patient safety and spur growth through pharmacovigilance automation.
Latest:
Q&A With Daniel Lofaso, CEO of Digital ElevatorLofaso discusses strategies that biotech companies can take once its time to make the big push.
